This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2012 Oct 10;30(29):e299.

doi: 10.1200/JCO.2012.41.7923. Epub 2012 Sep 4.

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia

Sosipatros A Boikos¹, Hans-Joerg Hammers

Affiliations

PMID: 22949145
DOI: 10.1200/JCO.2012.41.7923

Case Reports

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia

Sosipatros A Boikos et al. J Clin Oncol. 2012.

. 2012 Oct 10;30(29):e299.

doi: 10.1200/JCO.2012.41.7923. Epub 2012 Sep 4.

Authors

Sosipatros A Boikos¹, Hans-Joerg Hammers

Affiliation

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, CRB 186-Oncology, Baltimore, MD 21231, USA. sboikos1@jhmi.edu

PMID: 22949145
DOI: 10.1200/JCO.2012.41.7923

No abstract available

PubMed Disclaimer

Similar articles

Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J, Newby Y, Sundar S. Adhikaree J, et al. BMJ Case Rep. 2014 Jan 30;2014:bcr2013202861. doi: 10.1136/bcr-2013-202861. BMJ Case Rep. 2014. PMID: 24481018 Free PMC article.
Denosumab and bone metastases. No better than a bisphosphonate.
[No authors listed] [No authors listed] Prescrire Int. 2012 Sep;21(130):204-6. Prescrire Int. 2012. PMID: 23016249 Review.
Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
Massaro AM. Massaro AM. Cancer Pract. 2002 Jul-Aug;10(4):219-21. doi: 10.1046/j.1523-5394.2002.104006.x. Cancer Pract. 2002. PMID: 12100107 No abstract available.
Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A, El-Amm J, Aragon-Ching JB. Freeman A, et al. Clin Genitourin Cancer. 2013 Dec;11(4):e24-6. doi: 10.1016/j.clgc.2013.06.002. Epub 2013 Sep 2. Clin Genitourin Cancer. 2013. PMID: 24007982 No abstract available.
Hypercalcemia and bone resorption in malignancy.
Walls J, Bundred N, Howell A. Walls J, et al. Clin Orthop Relat Res. 1995 Mar;(312):51-63. Clin Orthop Relat Res. 1995. PMID: 7634618 Review.

See all similar articles

Cited by

Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S, Hu MI. Thosani S, et al. Future Oncol. 2015;11(21):2865-71. doi: 10.2217/fon.15.232. Epub 2015 Sep 25. Future Oncol. 2015. PMID: 26403973 Free PMC article. Review.
Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia.
Abd Jalil AA, Wan Muhamad Hatta SF, Mohamad AF, Abdul Rani MF. Abd Jalil AA, et al. Case Rep Med. 2021 Apr 19;2021:5544848. doi: 10.1155/2021/5544848. eCollection 2021. Case Rep Med. 2021. PMID: 33986809 Free PMC article.
Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N, Nakajima K, Nakamura Y, Kobayashi M, Shirahata K, Maeda C, Uehara T, Gomi D, Ito N. Ashihara N, et al. Intern Med. 2016;55(23):3453-3457. doi: 10.2169/internalmedicine.55.7134. Epub 2016 Dec 1. Intern Med. 2016. PMID: 27904108 Free PMC article.
Denosumab for management of severe hypercalcemia in primary hyperparathyroidism.
Eremkina A, Krupinova J, Dobreva E, Gorbacheva A, Bibik E, Samsonova M, Ajnetdinova A, Mokrysheva N. Eremkina A, et al. Endocr Connect. 2020 Oct;9(10):1019-1027. doi: 10.1530/EC-20-0380. Endocr Connect. 2020. PMID: 33112830 Free PMC article.
Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
Valdes-Socin H, Almanza MR, Fernández-Ladreda MT, Daele DV, Polus M, Chavez M, Beckers A. Valdes-Socin H, et al. Arch Endocrinol Metab. 2017 Sept-Oct;61(5):506-509. doi: 10.1590/2359-3997000000291. Epub 2017 Sep 18. Arch Endocrinol Metab. 2017. PMID: 28977163 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information